GRFS and GRF Related Headlines
Go Back- Grifols completes patient follow-up in phase 3 alpha-1 lung study
- Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
- Grifols starts two Phase 3 trials to expand immunoglobulin labels
- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- Grifols launches FESILTY fibrinogen concentrate in the US
- Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
- Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
GRFS and GRF Related Press Releases
Go Back- Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
- Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
GRFS and GRF Related SEC Filings
Go Back- Form 6-K Grifols SA For: Jul 30
- Form 6-K Grifols SA For: May 15
- Form SCHEDULE 13G/A Grifols SA Filed by: BRANDES INVESTMENT PARTNERS, LP
- Form 6-K Grifols SA For: May 07
- Form 20-F Grifols SA For: Dec 31
- Form SCHEDULE 13G/A Grifols SA Filed by: BRANDES INVESTMENT PARTNERS, LP
- Form 6-K Grifols SA For: Dec 16
